💊🌍 LUPIN | Product Launch Update
🚀 LUPIN has launched Bosentan Tablets for Oral Suspension, 32 mg in the US.
✅ Secured 180-day generic drug exclusivity
✅ Targets an estimated $10M annual market
✅ Launch enabled through US FDA approval via alliance partner NATCO Pharma
⚡ This launch strengthens LUPIN US portfolio while capturing early-mover advantage in a niche therapy segment.
#StockInNews#WatchOutFor
853 likes·54 comments